Description

Rifaximin is a semi-synthetic, non-systemic antibiotic derived from rifamycin, specifically engineered for targeted action within the gastrointestinal tract. Its primary value lies in its minimal systemic absorption, making it a cornerstone for treating gastrointestinal infections and conditions like traveler's diarrhea and hepatic encephalopathy. This product is essential for pharmaceutical manufacturers, research institutions, and contract development organizations engaged in producing oral solid dosage forms, clinical research, and advanced drug development. We supply high-purity Rifaximin CAS NO 80621-81-4 to support global pharmaceutical supply chains with reliable, quality-assured active pharmaceutical ingredients.

Application

• Pharmaceutical API: Primary use as the active pharmaceutical ingredient in the manufacture of oral tablets and capsules for treating traveler's diarrhea caused by non-invasive strains of *Escherichia coli*.
• Hepatic Encephalopathy Management: Key component in medication for reducing the risk of overt hepatic encephalopathy recurrence in adults.
• Irritable Bowel Syndrome with Diarrhea (IBS-D): Used in formulations for the treatment of IBS-D in adult patients.
• Clinical Research & Development: Serves as a reference standard and raw material in preclinical studies and clinical trials for new gastrointestinal therapeutics.
• Contract Manufacturing: Supplied to CDMOs for the production of finished dosage forms under current Good Manufacturing Practice (cGMP) guidelines.
• Veterinary Pharmaceutical Research: Investigated for potential applications in veterinary medicine for gastrointestinal disorders in animals.

Basic Information

Product Name	Rifaximin
CAS No.	80621-81-4
Molecular Formula	C43H51N3O11
Molecular Weight	785.89 g/mol
Synonyms	Rifaximin; Rifaximina; Rifaximinum; L-105; Rifamycin L 105; Rifamycin SV 105; 4-Deoxy-4'-methylpyrido[1',2'-1,2]imidazo[5,4-c]rifamycin SV; Normix; Xifaxan; Rifagut; Spiraxin; Zaxine; Flonorm; Redactiv
EINECS	Contact for details

Quality Control

Our Rifaximin is manufactured and tested to meet stringent pharmacopeial standards, including USP and EP monographs. Every batch undergoes rigorous quality testing for identity, potency, purity, and specified impurities. Comprehensive analytical methods such as HPLC, related substances tests, and residual solvent analysis are employed. A Certificate of Analysis (COA) documenting all test results is provided with each shipment, ensuring full traceability and compliance with cGMP and relevant regulatory requirements for global markets.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive); the container must be kept tightly sealed in a dry environment to prevent degradation. For long-term stability, store under inert conditions if specified.

Specification

Item	Specification
Appearance	Orange-red crystalline powder
Identification (IR)	Conforms to standard
Identification (HPLC)	Retention time corresponds to reference
Assay (HPLC)	98.0% - 102.0% (on dried basis)
Loss on Drying	≤ 2.0%
Residue on Ignition	≤ 0.1%
Related Substances (HPLC)	Individual impurity: ≤ 0.5% Total impurities: ≤ 2.0%
Heavy Metals	≤ 20 ppm
Microbial Enumeration Tests	Meets USP/EP criteria

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.